Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-266-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$670,000.00
Profitability
Miscellaneous
Employees34
OptionableOptionable
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.04. View Sunesis Pharmaceuticals' Earnings History.
When is Sunesis Pharmaceuticals' next earnings date?
What price target have analysts set for SNSS?
3 brokerages have issued twelve-month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $0.50 to $4.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $2.25 in the next twelve months. This suggests a possible upside of 376.7% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.
What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals.
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
News stories about SNSS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals saw a decrease in short interest during the month of December. As of December 14th, there was short interest totalling 330,733 shares, a decrease of 40.6% from the November 30th total of 556,956 shares. Based on an average daily volume of 729,195 shares, the short-interest ratio is currently 0.5 days. Approximately 1.2% of the company's stock are short sold. View Sunesis Pharmaceuticals' Current Options Chain.
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Mersana Therapeutics (MRSN), BioXcel Therapeutics (BTAI), Acasti Pharma (ACST), Ovid Therapeutics (OVID), Pharmaxis (PXSLY), Tiziana Life Sciences (TLSA), Iterum Therapeutics (ITRM), Humanigen (HGEN), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Alpine Immune Sciences (ALPN), Tetraphase Pharmaceuticals (TTPH), Medicure (MCUJF), Elite Pharmaceuticals (ELTP) and Infinity Pharmaceuticals (INFI).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
- Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox, Chief Scientific Officer
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $0.4720.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $22.03 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.
What is Sunesis Pharmaceuticals' official website?
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
